Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics.
February 31, 2024
Share
Myriad Genetics, Inc. (NasdaqGS:MYGN) entered into definitive agreement to acquire select assets of laboratory business of Intermountain Precision Genomics on January 18, 2024. The assets include laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG?s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The transaction is expected to close on February 1, 2024, subject to customary closing conditions.
Myriad Genetics, Inc. (NasdaqGS:MYGN) completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics on February 1, 2024.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
MYRIAD GENETICS, INC. 
